Skip to main content
OpenTrials
Completed

NCT Number: NCT00561769

Luteal Phase Commencing of Growth Hormone

Commencing of growth hormone in luteal phase when follicular cohort for the next cycle is being gathered may increase mature oocytes in poor responder

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Infertility Genital Diseases Urogenital Diseases

Age range

20 year–40 year

Sex eligibility

Female

Study type

Observational

Primary location

Ren Tıp ART Center

Bursa, 16200, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Poor responder

Exclusion criteria

  • FSH >20 IU

Treatment and study plan

Norditropin pen

Drug

12 IU per day

Primary outcomes

  1. mature oocyte number

    Time frame: 2 years

Secondary outcomes

  1. pregnancy rate

    Time frame: 2 years

Interested in participating?

Completed

Looking for future studies?

Notify Me

Sponsors and collaborators

Lead sponsor

Gulhane School of Medicine

Other

Collaborators

  • Ren-Tıp ART Center, Bursa, Turkey

Registry information

Official study title

Growth Hormone co-Treatment Within a GnRH Agonist Long Protocol in Patients With Poor Ovarian Response

Important dates

Study start
2005
Study completion
2007
First posted
Nov 21, 2007
Registry last updated
Nov 21, 2007

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.